#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14916	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2069	713.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1416	1416	C	838	C	820	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26708	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3562	745.6	0	.	n	.	0	T695C	SNP	695	695	T	1112	1112	C	792	C	768	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26708	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3562	745.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1754	1754	A	882	A,G	865,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26708	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3562	745.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2388	2388	C	803	C	784	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26708	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3562	745.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3014	3014	T	782	T,C	765,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26708	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3562	745.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2462	2462	A	808	A	791	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	0	10	blaTEM	861	210	100.0	blaTEM.l6.c30.ctg.1	277	1.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	0	10	blaTEM	861	239	100.0	blaTEM.l6.c30.ctg.2	306	2.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2000	folP	852	852	100.0	folP.l15.c4.ctg.1	1625	122.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1095	1097	AGC	190;192;195	A;G;C	186;187;186	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5398	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3481	154.3	1	SNP	p	S91F	0	.	.	271	273	TCC	633	635	TCC	175;173;177	T;C;C	170;168;173	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5398	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3481	154.3	1	SNP	p	D95G	0	.	.	283	285	GAC	645	647	GAC	189;188;187	G;A;C	184;180;184	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5398	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3481	154.3	1	SNP	p	D95N	0	.	.	283	285	GAC	645	647	GAC	189;188;187	G;A;C	184;180;184	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1416	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1283	109.9	0	.	p	.	0	C66trunc	TRUNC	196	196	T	520	520	T	169	T	166	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1416	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1283	109.9	0	.	p	.	0	D79N	NONSYN	235	237	GAT	559	561	AAT	172;174;172	A;A;T	168;167;165	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1416	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1283	109.9	0	.	p	.	0	G83E	NONSYN	247	249	GGG	571	573	GAA	168;166;167	G;A;A	160;163;162	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1416	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1283	109.9	0	.	p	.	0	A86T	NONSYN	256	258	GCG	580	582	ACG	178;181;179	A,C;C;G	167,1;178;175	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1416	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1283	109.9	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	637	639	CAC	201;199;200	C;A;C	197;192;197	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1416	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1283	109.9	0	.	p	.	0	A134T	NONSYN	400	402	GCA	724	726	ACA	161;163;163	A,G;C;A	156,1;159;161	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1416	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1283	109.9	1	SNP	p	G45D	0	.	.	133	135	GGC	457	459	GGC	197;194;189	G;G;C	194;191;188	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4792	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2897	164.6	1	SNP	p	D86N	0	.	.	256	258	GAC	509	511	GAC	165;166;166	G;A;C,T	159;155;161,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4792	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2897	164.6	1	SNP	p	S87I	0	.	.	259	261	AGT	512	514	AGT	167;170;172	A;G;T	162;166;161	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4792	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2897	164.6	1	SNP	p	S87R	0	.	.	259	261	AGT	512	514	AGT	167;170;172	A;G;T	162;166;161	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4792	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2897	164.6	1	SNP	p	S87W	0	.	.	259	261	AGT	512	514	AGT	167;170;172	A;G;T	162;166;161	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4792	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2897	164.6	1	SNP	p	S88P	0	.	.	262	264	TCC	515	517	TCC	175;174;173	T;C;C	168;170;169	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4060	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2795	144.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1609	1611	GGC	185;184;181	G;G,T;C	181;176,1;172	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1283	1285	GCA	201;201;202	G;C;A	195;197;199	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1286	1288	ATC	202;202;203	A;T,C;C	200;197,1;201	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1298	1300	GTG	203;203;202	G;T,C;G	198;198,1;197	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1298	1300	GTG	203;203;202	G;T,C;G	198;198,1;197	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1802	1804	ACC	183;181;182	A;C;C	174;175;178	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1856	1858	GCG	151;152;150	G;C,G;G	138;125,3;145	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1856	1858	GCG	151;152;150	G;C,G;G	138;125,3;145	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1979	1981	GGC	153;152;151	G;G;C	151;149;149	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1988	1990	GGC	145;141;140	G;G;C	140;136;133	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3690	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2494	146.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2006	2008	CCG	114;114;113	C;C,G;G	109;105,1;100	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5600	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3041	183.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2374	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1929	122.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	618	618	C	141	C	135	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	473	475	GGA	224;223;226	G;G;A	221;219;223	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	0	.	p	.	0	F135L	NONSYN	403	405	TTT	734	736	CTT	211;208;209	C,G;T;T,G	205,1;204;203,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	758	760	GGA	220;217;218	G,A;G,A;A	212,1;212,1;207	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	0	.	p	.	0	D171G	NONSYN	511	513	GAT	842	844	GGT	215;214;217	G,A;G;T	207,2;209;201	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	0	.	p	.	0	G189S	NONSYN	565	567	GGC	896	898	AGC	192;188;184	A;G;C,G	187;183;180,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	962	962	T	190	T	177	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	1	SNP	p	G120K	0	.	.	358	360	GGT	689	691	GGT	193;192;191	G,A;G,A;T,G	188,1;189,1;177,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	1	SNP	p	A121D	0	.	.	361	363	GCC	692	694	GCC	191;189;192	G;C,A;C	187;185,1;187	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2740	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1609	169.3	1	SNP	p	A121N	0	.	.	361	363	GCC	692	694	GCC	191;189;192	G;C,A;C	187;185,1;187	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10234	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4870	209.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2023	2025	AAT	223;220;220	A;A;T	220;217;215	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1160	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1111	103.8	1	SNP	p	V57M	1	.	.	169	171	ATG	485	487	ATG	239;239;238	A;T;G	233;233;228	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
